載入中
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
收盤時
US$1.22
−US$0.005 · -0.41%
盤後
US$1.23
+US$0.01 · +0.82%
10月12日 下午4:26 ET
盤中時間採用ET。市場資料可能有所延遲。
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
日內區間
目前US$1.22
52週區間
目前US$1.22
盤中時間採用ET。市場資料可能有所延遲。
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
日內區間
目前US$1.22
52週區間
目前US$1.22
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.84億 USD | 7699.4萬 USD | 23.7萬 USD | 59.6萬 USD | 139.3萬 USD |
| 銷貨成本 | 474.5萬 USD | 125.6萬 USD | — | — | — |
| 毛利 | 1.79億 USD | 7573.8萬 USD | 23.7萬 USD | 59.6萬 USD | 139.3萬 USD |
| 研究與開發 | 7371.5萬 USD | 1.04億 USD | 1.25億 USD | 9551.8萬 USD | 8572.7萬 USD |
| 銷售、一般及管理費用 | 1.59億 USD | 1.46億 USD | 6913.5萬 USD | 4362.8萬 USD | 2966.5萬 USD |
| 營業費用 | 2.33億 USD | 2.49億 USD | 1.94億 USD | 1.39億 USD | 1.15億 USD |
| 利息收入 | 1811.7萬 USD | 1960.7萬 USD | 1815.2萬 USD | 252.9萬 USD | 52.7萬 USD |
| 利息支出 | 3265.7萬 USD | 1850.4萬 USD | 831.2萬 USD | 688.2萬 USD | 374萬 USD |
| 折舊和攤銷 | 120.4萬 USD | 122.1萬 USD | 103.3萬 USD | 86.8萬 USD | 78.3萬 USD |
| 營業利益 | −5383.5萬 USD | −1.74億 USD | −1.94億 USD | −1.39億 USD | −1.14億 USD |
| 淨利 | −8578.2萬 USD | −1.75億 USD | −1.84億 USD | −1.42億 USD | −1.16億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2014年7月22日 | 529:500 | — | — |
已生效 2014年7月22日
529:500
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
